Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $30,338.88 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 676 shares of Akero Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total value of $30,338.88. Following the completion of the sale, the chief financial officer now directly owns 61,959 shares of the company’s stock, valued at $2,780,719.92. The trade was a 1.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Akero Therapeutics Stock Down 1.6 %

AKRO opened at $44.15 on Monday. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -11.77 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm’s fifty day moving average is $42.10 and its 200 day moving average is $33.89. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). On average, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AKRO shares. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Canaccord Genuity Group boosted their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. UBS Group boosted their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Finally, Citigroup raised their target price on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics has an average rating of “Buy” and a consensus target price of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AKRO. GF Fund Management CO. LTD. bought a new position in shares of Akero Therapeutics during the fourth quarter worth $41,000. Sterling Capital Management LLC lifted its stake in Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after purchasing an additional 1,582 shares in the last quarter. Quarry LP bought a new position in shares of Akero Therapeutics during the 4th quarter valued at about $83,000. Summit Investment Advisors Inc. increased its holdings in shares of Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares during the last quarter. Finally, Summit Financial Wealth Advisors LLC bought a new stake in shares of Akero Therapeutics in the third quarter worth about $205,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.